Cargando…
Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?
Oncolytic viruses (OVs) preferentially target and kill cancer cells without affecting healthy cells through a multi-modal mechanism of action. While historically the direct killing activity of OVs was considered the primary mode of action, initiation or augmentation of a host antitumor immune respon...
Autores principales: | Davola, Maria Eugenia, Mossman, Karen Louise |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492965/ https://www.ncbi.nlm.nih.gov/pubmed/31069150 http://dx.doi.org/10.1080/2162402X.2019.1596006 |
Ejemplares similares
-
Oncolytic BHV-1 Is Sufficient to Induce Immunogenic Cell Death and Synergizes with Low-Dose Chemotherapy to Dampen Immunosuppressive T Regulatory Cells
por: Davola, Maria Eugenia, et al.
Publicado: (2023) -
Improving the therapeutic efficacy of oncolytic viruses for cancer: targeting macrophages
por: Shen, Zhen, et al.
Publicado: (2023) -
Oncolytic viruses as therapeutic cancer vaccines
por: Bartlett, David L, et al.
Publicado: (2013) -
Oncolytic Viruses: Therapeutics With an Identity Crisis
por: Breitbach, Caroline J., et al.
Publicado: (2016) -
Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective
por: Garmaroudi, Ghazal Asadi, et al.
Publicado: (2022)